Marquardt Jens U, Edlich Frank
Department of Medicine I, University Medical Center Schleswig-Holstein, Lübeck, Germany.
Department of Medicine, Lichtenberg Research Group, University Mainz, Mainz, Germany.
Front Oncol. 2019 Dec 13;9:1421. doi: 10.3389/fonc.2019.01421. eCollection 2019.
Hepatocellular carcinoma (HCC) ranks among the most rapidly evolving cancers in the Western world. The majority of HCCs develop on the basis of a chronic inflammatory liver damage that predisposes liver cancer development and leads to deregulation of multiple cellular signaling pathways. The resulting dysbalance between uncontrolled proliferation and impaired predisposition to cell death with consecutive failure to clear inflammatory damage is a key driver of malignant transformation. Therefore, resistance to death signaling accompanied by metabolic changes as well as failed immunological clearance of damaged pre-neoplastic hepatocytes are considered hallmarks of hepatocarcinogenesis. Hereby, the underlying liver disease, the type of liver damage and individual predisposition to apoptosis determines the natural course of the disease as well as the therapeutic response. Here, we will review common and individual aspects of cell death pathways in hepatocarcinogenesis with a particular emphasis on regulatory networks and key molecular alterations. We will further delineate the potential of targeting cell death-related signaling as a viable therapeutic strategy to improve the outcome of HCC patients.
肝细胞癌(HCC)是西方世界中发展最为迅速的癌症之一。大多数HCC是在慢性炎症性肝损伤的基础上发生的,这种损伤易引发肝癌,并导致多种细胞信号通路失调。由此产生的不受控制的增殖与细胞死亡易感性受损之间的失衡,以及随之而来的清除炎症损伤的失败,是恶性转化的关键驱动因素。因此,对死亡信号的抵抗以及伴随的代谢变化,还有受损的癌前肝细胞的免疫清除失败,都被认为是肝癌发生的标志。在此过程中,潜在的肝脏疾病、肝损伤类型以及个体对凋亡的易感性决定了疾病的自然进程以及治疗反应。在此,我们将回顾肝癌发生过程中细胞死亡途径的共性和个体差异,特别强调调控网络和关键分子改变。我们还将进一步阐述靶向细胞死亡相关信号作为一种可行的治疗策略,以改善HCC患者预后的潜力。